On 24 June, the pharmaceutical company Enterin, which develops novel compounds to treat Parkinson's disease, announced the enrolment of the first research participant with Parkinson's Disease Dementia (PDD) to the DEMET study. The Phase I clinical trial is evaluating the tolerability and efficacy of repeated oral doses of ENT-01 for the treatment of PDD. ENT-01 is a synthetic derivative of squalamine, which is not absorbed into the bloodstream. The compound was recently shown to improve both motor and non-motor symptoms for the treatment of Parkinson’s disease related constipation, with the potential to modify the disease progression. The company is aiming to recruit around 30 participants over a 6-month period in the US.
Enterin announces Phase I study evaluating ENT-01 for Parkinson's disease dementia
24/06/2019
